Table 1.

Demographics of subjects that were retrospectively analyzed in this work. Age is represented as mean ± standard deviation. MMSE is also represented as mean ± standard deviation. All the 109 subjects who received solanezumab were amyloid-positive and mild to moderate AD cases. YCN young cognitively normal, CN cognitively normal, MCI mild cognitive impairment, AD Alzheimer’s disease, N number of subjects, MMSE Mini-Mental State Examination, F female, M male. CD college degree or higher, HS high school or lower, C Caucasian, NC Not Caucasian (Asian, Black or African American, Other)

	YCN/Aβ-	CN/Aβ-	CN/Aβ+	MCI/Aβ-	MCI/Aβ+	AD/Aβ-	AD/Aβ+
N	16	53	5	50	47	16	240
Age	28.9 ± 4.9	67.6 ± 10.2	77.8 ± 7.0	69.1 ± 9.3	72.7 ± 9.1	72.2 ± 6.9	73.7 ± 8.3
MMSE	29.6 ± 0.5	29.5 ± 0.5	29.6 ± 0.5	28.2 ± 1.7	27.4 ± 1.8	22.9 ± 3.2	22.5 ± 2.9
Sex	7F/9M	24F/29M	2F/3M	27F/23M	21F/26M	7F/9M	135F/104M
Education	15CD/1HS	45CD/8HS	4CD/1HS	37CD/13HS	38CD/9HS	14CD/2HS	141CD/97HS
Race	11C/5NC	42C/11NC	5C/0NC	43C/7NC	45C/2NC	14C/2NC	192C/22NC